REGENXBIO Inc. (RGNX): Total Liabilities
$350.30M
As of 2025-12-31
$314.85M
As of 2026-06-30
+3.4%
3-year compound annual growth
+1.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $350.30M | +69.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $206.34M | -21.3% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $262.23M | -17.3% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $317.07M | -9.3% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $349.61M | +5.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $330.41M | +592.5% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $47.71M | +36.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $34.97M | +123.5% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $15.65M | +42.3% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $10.99M | +140.5% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $4.57M | -50.2% | 2017-03-07, Balance as of period end |
| 2014-12-31 | $9.19M | n/a | 2016-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗